Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

ClinicalTrials.gov ID: NCT02622321

Public ClinicalTrials.gov record NCT02622321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors

Study identification

NCT ID
NCT02622321
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
113 participants

Conditions and interventions

Conditions

Interventions

  • Emicizumab Drug
  • rFVIIa Drug
  • aPCC Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 17, 2015
Primary completion
Oct 24, 2016
Completion
Nov 30, 2020
Last update posted
Jun 23, 2021

2015 – 2020

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Children's Hospital Los Angeles Los Angeles California 90010
Santa Monica Oncology Center Santa Monica California 90403
University of Colorado Denver, Children's Hospital Aurora Colorado 80045
Winship Cancer Institute Atlanta Georgia 30322
Boston Childrens Hospital Boston Massachusetts 02115
Children's Hospital of Michigan; Pediatrics Detroit Michigan 48201
Cornell Univ Medical College; Hematology-Oncolog New York New York 10021
Oregon Health & Science Uni ; Dept of Pediatrics Portland Oregon 97201
Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046 Hershey Pennsylvania 17033-0850
Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr Houston Texas 77030
Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02622321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 23, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02622321 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →